随机双盲,安慰剂对照试验的德斯莫普林因脏活检后出血
Narayan Prasad1, Jeyakumar Meyyappan1, Deependra Kumar Yadav1
1Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Kidney international reports
|July 18, 2025
概括
在脏活检后,德斯摩素显著减少了出血和血液瘤. 这种药物为接受脏活检手术的患者预防并发症提供了安全有效的选择.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 临床药理学 临床药理学
背景情况:
- 脏活检是一个至关重要的诊断程序.
- 活检后出血是一种常见的并发症,需要采取有效的预防措施.
研究的目的:
- 为了评估德斯莫普林素在减少活检后出血方面的疗效和安全性.
- 评估德斯莫普林素对二次出血相关结果和不良事件的影响.
主要方法:
- 一个双盲,随机,安慰剂控制的试验,涉及203名接受脏活检的患者.
- 患者在手术前一小时接受了德斯莫普林素 (300微克鼻入) 或安慰剂.
- 主要结局是活检后出血;次要结局包括血红蛋白下降,血瘤和需要干预.
主要成果:
- 德斯莫普林显著降低出血发生率 (11.9%与33.3%,P=0.0003) 和血液瘤形成 (11.9%与30.4%,P=0.001).
- 在不同的估计膜过率 (eGFR) 类别中观察到减少出血.
- 服用后发现 VIII 因子和·维莱布兰德因子水平升高;低血量和头痛更为常见的副作用.
结论:
- 德斯莫普林在减少脏活检中的活检后出血和血液瘤方面是有效的.
- 该药物提供了一个可行的预防方案,具有可控的副作用.
- 进一步的研究是有必要的,以探索更广泛的临床应用的desmopressin.
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
58
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
58
01:26Kidney Transplant II: Surgical Procedure
77
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
77
01:11Blinding
2.6K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.6K